Skip to main content

American College of Cardiology (ACC) 2015 Annual Scientific Sessions

March 16-18, 2015; San Diego, CA


Rivaroxaban Reversal Agent Safe and Effective, Trial Finds: A Potential Universal Antidote for Factor Xa Inhibitors?

Although the novel oral anticoagulants targeting factor Xa have many advantages over warfarin, one major limitation of their use has been the absence of a specific reversal agent. But at the ACC Scientific Sessions, results from a phase 3 trial were presented showing safety and efficacy of andexanet alfa in reversing the effects of rivaroxaban.

Read More>>

 

 

Combination Ezetimibe/Simvastatin Reduces First and Total Cardiovascular Events Better Than Simvastatin Alone

A subanalysis of IMPROVE-IT data showed that that intensive lipid-lowering therapy is important to continue long-term even after patients have had a CV event.

Read More>>

 

 

Invasive Therapy Better Than Conservative Therapy in Elderly Patients With NSTE-ACS

At the ACC 2015 Scientific Sessions, Nicolai Koulmann Tegn, MD, Rikshospitalet Oslo University Hospital, Norway, and colleagues presented the results of the After Eighty Study, a randomized, multicenter trial that assessed adverse cardiovascular outcomes following invasive versus conservative therapy among elderly patients (>80 years) with non-ST-elevation ACS (NSTE-ACS).

Read More>>

 

 

Weight Loss Associated With Improvement in Atrial Fibrillation Burden

At the ACC 2015 Scientific Sessions, a team of Australia-based researchers presented the findings of the LEGACY study (Long-Term Effect of Goal-Directed Weight Management in an Atrial Fibrillation Cohort: A Long-Term Follow-up Study). Their goal was to examine whether weight loss is associated with reduced burden in patients with atrial fibrillation (AF).

Read More>>

Back to Top